Practices received a CAS alert on 2 November 2026 notifying them of the circulation of influenza in the community early in the season with Influenza A (H1N1) and (H3N2) dominant strains.
In addition to encouraging uptake of the flu vaccine, it advised practices that they should consider prompt antiviral treatment and post-exposure prophylaxis for eligible patients as per NICE guidance. Following an update in October 2025 by DHSC, practices and community pharmacies can now prescribe and dispense oseltamivir (Tamiflu) and zanamivir (Relenza) without seasonal restrictions.
UKHSA have updated their guidance to reflect this, recommending that treatment or post-exposure prophylaxis with antiviral medication for at risk groups should be initiated within 48 hours of commencement of symptoms to help reduce the risk of complications and improve clinical outcomes. Studies have shown some benefit when given up to five days after symptom onset, but please note this is an off-license indication.
At risk groups include:
- People ages over 65 years
- Children aged up to 6 months
- Pregnant women (at any stage of pregnancy and up to two weeks postpartum)
- People with asplenia or dysfunction of the spleen
- Chronic respiratory, heart, kidney, liver or neurological disease
- Diabetes mellitus
- Immunosuppression
- Morbid obesity (BMI of 40 or more)
The first line treatment is usually with oral oseltamivir, but where H1N1 strains are dominant as has been confirmed for the 2026/27 season, practices should consider using zanamivir in severely immunocompromised patients due to higher likelihood of oseltamivir resistance. Further prescribing guidance is available on the NICE website.
Local Pharmacy Committee representatives have confirmed that not all pharmacies in London will have oseltamivir and/or zanamivir in stock due to risk of wastage and associated costs. It may be helpful to refer to local prescribing guidelines in these instances for local arrangements e.g. through hospital pharmacies. While baloxivir is a licensed antiviral medication for influenza in the UK, it is highly unlikely that this will be available locally except through specialist arrangements.